LORENA TONARELLI, MSc

Freelance Medical Writer

Senior consultant in market access/HEOR

VALUE STRATEGY & COMMUNICATION SPECIALIST

Oncology (multiple myeloma, leukaemia, lymphoma, retinoblastoma, and brain, breast, ovarian, lung, kidney, pancreatic, prostate and skin cancers) | Neurology (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy) | Cardiovascular (stroke, myocardial infarction, heart failure, arrhythmias) | Dermatology (psoriasis, atopic dermatitis) | Diabetes and complications (nephropathy, retinopathy) | Rare diseases (cystic fibrosis) | Primary and secondary immunodeficiency disorders | Respiratory (asthma, COPD, seasonal and pandemic influenza) | Ophthalmology (AMD, glaucoma) | Rheumatology |

Checkpoint inhibitors (anti PD-1/PD-L1 and CTLA-4 mAbs) | PARP inhibitors | tyrosine kinase inhibitors (VEGFR TKIs, HER2 TKIs) | CDK4/6 inhibitors | EGFR/cMet bispecific antibodies | anti-CD30 and anti-C4.4a antibody-drug conjugates | immunomodulatory/antineoplastic agents | PCSK9 inhibitors | SGLT2 inhibitors| factor Xa inhibitors | angiotensin receptor-neprilysin inhibitors | aldosterone synthase inhibitors | guanylyl cyclase activators | CX3CR1-binding agents | recombinant human GLP-2 analogues | anti-TNF monoclonal antibodies | IL-23 inhibitors | IL-4/IL-13 signalling inhibitorLAMAs, LABAs, and their combinations | CFTR potentiatorsimmunoglobulins |

Print Print | Sitemap
© 2020 Lorena Tonarelli, M.Sc. B.Sc. (Hons)